|
Mark Lowdell PhD, FRCPath, FRSB
CSO
InMuneBio Inc
London
UK
|
Professor Mark Lowdell PhD FRCPath FRSB is the Professor of Cell & Tissue Therapy at University College London, CSO of INmuneBio Inc and founder of the Centre for Cell, Gene & Tissue Therapeutics at Royal Free Hospital London. He is a qualified diagnostic immunopathologist as well as holding MHRA Qualified Person status for the release of ATMPs for clinical trials. He served two terms as Vice President (Europe) of the International Society for Cell & Gene Therapy (ISCT) and has over 30 years’ experience in cell and gene therapy. Much of his career has centred on adoptive immunotherapy of cancer and has targeted the role of the innate immune responses; especially the role of natural killer (NK) cells, although his experience includes a variety of adoptive T cell therapies (cancer and viral infection) as well as CAR-T cells, dendritic cell vaccines and mesenchymal stromal cells (MSCs).
He designed and established the first academic GMP facility in the UK for the production of human cells as medicines in 2003. This GMP facility produced the first somatic cell medicine for clinical trial in the UK, a tumour-primed allogeneic NK cell ATMP invented by Professor Lowdell for a trial in refractory AML. This was followed by a multicentre trial in the US and finally developed into a 2nd generation NK-priming drug; INKmune which is in a multicentre phase I/II trial in MDS in Europe and a second multicentre trial in metastatic prostate cancer in the USA.
Professor Lowdell has run multiple basic science research groups covering all aspects of cellular immunotherapy from anti-viral T cells, TIL cells and NK cells in cancer, to autologous dendritic cells and CAR-T cells. In parallel he has run a team focussed on tissue engineering with MSC-seeded scaffolds and led the translation to first-in-human clinical applications.
Professor Lowdell’s recent academic grant awards exceed £3m and cover immunotherapy of cancer with NK, CAR-T and gene-modified MSCs and immunomodulation of inflammation and autoimmunity with allogeneic MSCs. Prior to his retirement from the Royal Free Hospital, he was awarded national funding as a UK Hub for Gene Therapy by the UK MRC.
Professor Lowdell has held and holds numerous appointments to academic and government advisory boards in the UK and overseas. He was a member of the UK Government Regenerative Medicine Expert Review Group and is a member of the scientific advisory boards, consultant to or founder of many of the key companies involved in ATMP development in the EU and USA. He co-founded INmune Bio Inc in 2016 which IPO’d on Nasdaq in 2019 and Achilles Therapeutics Ltd in 2016 which completed its IPO in 2021. He is a co-founder of a GMP software company, Autolomous Ltd, and a scientific advisor to Advent Bio Ltd, Autolus Ltd, Avectas Ltd, Cytoseek Ltd, NWBio Therapeutics Inc, Sartorius GmbH, Quell Therapeutics Ltd and ViroCell Biologics Ltd.
He designed and established the first academic GMP facility in the UK for the production of human cells as medicines in 2003. This GMP facility produced the first somatic cell medicine for clinical trial in the UK, a tumour-primed allogeneic NK cell ATMP invented by Professor Lowdell for a trial in refractory AML. This was followed by a multicentre trial in the US and finally developed into a 2nd generation NK-priming drug; INKmune which is in a multicentre phase I/II trial in MDS in Europe and a second multicentre trial in metastatic prostate cancer in the USA.
Professor Lowdell has run multiple basic science research groups covering all aspects of cellular immunotherapy from anti-viral T cells, TIL cells and NK cells in cancer, to autologous dendritic cells and CAR-T cells. In parallel he has run a team focussed on tissue engineering with MSC-seeded scaffolds and led the translation to first-in-human clinical applications.
Professor Lowdell’s recent academic grant awards exceed £3m and cover immunotherapy of cancer with NK, CAR-T and gene-modified MSCs and immunomodulation of inflammation and autoimmunity with allogeneic MSCs. Prior to his retirement from the Royal Free Hospital, he was awarded national funding as a UK Hub for Gene Therapy by the UK MRC.
Professor Lowdell has held and holds numerous appointments to academic and government advisory boards in the UK and overseas. He was a member of the UK Government Regenerative Medicine Expert Review Group and is a member of the scientific advisory boards, consultant to or founder of many of the key companies involved in ATMP development in the EU and USA. He co-founded INmune Bio Inc in 2016 which IPO’d on Nasdaq in 2019 and Achilles Therapeutics Ltd in 2016 which completed its IPO in 2021. He is a co-founder of a GMP software company, Autolomous Ltd, and a scientific advisor to Advent Bio Ltd, Autolus Ltd, Avectas Ltd, Cytoseek Ltd, NWBio Therapeutics Inc, Sartorius GmbH, Quell Therapeutics Ltd and ViroCell Biologics Ltd.